FDA repays drug industry by rushing risky meds to market

FDA repays drug industry by rushing risky meds to market



As pharma companies underwrite three-fourths of the U.S. Food and Drug Administration’s budget for scientific reviews, the agency is increasingly fast-tracking expensive drugs with significant side effects and unproven health benefits.